VEGFR2/KDR Antagonist - 1 mg
- Cat.Number : AS-60628
- Manufacturer Ref. :
-
Availability :
In stock
This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.
Specifications
Chemistry | |
Sequence one letter code |
|
---|---|
Sequence three letter code |
|
Molecular Formula |
|
Molecular Mass/ Weight |
|
Modification | |
Conjugation |
|
Quantity & Purity | |
Purity |
|
Storage & stability | |
Form |
|
Storage Conditions |
|
Activity | |
Biomarker Target | |
Research Area | |
Sub-category Research Area | |
Usage |
|
Source | |
Source / Species |
|
Codes | |
Code Nacres |
|
You may also be interested in the following product(s)
![Image of a kit SensoLyte Rh110 Matriptase Activity Assay Kit Fluorimetric](/assets/cache/a73e7835-d2b3-4faf-af03-ba9116aa2011/500x500/as-72241-img-en-as-72241-01.jpg)
SensoLyte® Rh110 Matriptase Activity Assay Kit Fluorimetric - 1 kit
![Tube of Thrombospondin inhibitor peptide](/assets/cache/a7a0b397-7a22-4e15-9d4a-25b251cc1ab9/500x500/as-60877-img-en-as-60877-01.jpg)
Citations
Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway.
Invest Ophthalmol Vis Sci . 2013 Feb 18 ; 54(2) 918 | DOI : 10.1167/iovs.12-11291.
- H. Liu
- et al
Selective photodynamic therapy by targeted Verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2
Arch Ophthalmol. . 2004 Jul 01 ; 122(7) 1002 | DOI : 10.1001/archopht.122.7.1002
- RZ. Renno
- et al